Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of recombinant anti-coronavirus 19 hyperimmune gammaglobulin to treat high-risk and severely ill individuals infected with COVID-19

Trial Profile

Clinical trial of recombinant anti-coronavirus 19 hyperimmune gammaglobulin to treat high-risk and severely ill individuals infected with COVID-19

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2020

At a glance

  • Drugs Recombinant polyclonal antibody therapy - GigaGen (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors GigaGen
  • Most Recent Events

    • 09 Apr 2020 New trial record
    • 30 Mar 2020 According to a GigaGen media release,company expects to initiate trial in early 2021.

Trial Overview

Purpose

Clinical trial of recombinant anti-coronavirus 19 hyperimmune gammaglobulin to treat high-risk and severely ill individuals infected with COVID-19

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Sponsors GigaGen
  • Affiliations GigaGen

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
Recombinant polyclonal antibody therapy - GigaGenPrimary Drug Intravenous
-

Recombinant polyclonal antibody therapy

Trial Centres

Centres

Centre Name Location Trial Centre Country
GigaGen
-
-

Trial History

Event Date Event Type Comment
09 Apr 2020 New trial record New trial record Updated 09 Apr 2020
30 Mar 2020 Other trial event According to a GigaGen media release,company expects to initiate trial in early 2021. Updated 09 Apr 2020

References

  1. GigaGen. GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19. Media-Rel 2020;.

    Media Release
Back to top